Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.63 |
| ▸ | CDK2 | P24941 | 13/20 | 0.63 |
| ▸ | SGK1 | O00141 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12706273 | 0.89 | AKT1 (0.58) | AKT1CDK2SGK1HDAC1HDAC2 | |
| Trifluoroacetic Acid SCHEMBL1595385 | 0.86 | AKT1 (0.75) | AKT1CDK2SGK1 | |
| SCHEMBL3641191 | 0.84 | AKT1 (0.83) | AKT1CDK2SGK1 | |
| SCHEMBL3641195 | 0.84 | AKT1 (0.83) | AKT1CDK2SGK1 | |
| SCHEMBL3641199 | 0.84 | AKT1 (0.83) | AKT1CDK2SGK1 | |
| SCHEMBL1595117 | 0.83 | AKT1 (0.61) | AKT1CDK2SGK1FFAR1 | |
| SCHEMBL1595120 | 0.82 | AKT1 (0.53) | AKT1CDK2SGK1FFAR1HDAC1 | |
| SCHEMBL1744296 | 0.80 | AKT1 (0.45) | AKT1CDK2SGK1FFAR1 | |
| SCHEMBL3708170 | 0.80 | AKT1 (0.45) | AKT1CDK2SGK1FFAR1 | |
| SCHEMBL1744260 | 0.78 | AKT1 (0.43) | AKT1CDK2SGK1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2167504-A2 | THIADIAZOLE MODULATORS OF PKB | Amgen, Inc (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009011871-A2 | THIADIAZOLE MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | AKT1 29/4885CDK2 85/4885SGK1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.